Recursion Pharmaceuticals (RXRX) said Tuesday the first patient has been dosed in a phase 1 clinical study of REC-3565 for the potential treatment of relapsed or refractory B-cell lymphomas.
The investigational drug has demonstrated evidence of durable tumor regression in preclinical trials as a monotherapy and in combination with a BTK inhibitor, the company said.
The two-part study will also evaluate REC-3565 as a monotherapy to identify a recommended dose for combination regimens, Recursion Pharmaceuticals added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.